NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Note
1. Description of Business.
American
Cannabis Company, Inc. and its wholly owned subsidiary Company, Hollister & Blacksmith, Inc., doing business as American Cannabis
Consulting (“American Cannabis Consulting”), (collectively “the “Company”) are based in Denver, Colorado
and operate a fully-integrated business model that features end-to-end solutions for businesses operating in the regulated cannabis industry
in states and countries where cannabis is regulated and/or has been de-criminalized for medical use and/or legalized for recreational
use. We provide advisory and consulting services specific to this industry, design industry-specific products and facilities, and sell
both exclusive and non-exclusive customer products commonly used in the industry.
On
April 30, 2021, the Company closed its acquisition of the assets of Medihemp, LLC, and its wholly owned subsidiary SLAM Enterprises,
LLC, and Medical Cannabis Caregivers, Inc., each an entity organized and operating under the laws of the State of Colorado, and all doing
business as “Naturaleaf” in the medicinal cannabis industry in Colorado.
Naturaleaf
agreed to sell or assign to the Company the following assets:
|
1. |
Three
Medical Marijuana (MMC) Store Licenses; |
|
2. |
One Marijuana Infused Product
Licenses (MIPS); and |
|
3. |
One Option Premises Cultivation
License (OPC); and |
|
4. |
Related real property assets,
goodwill, and related business assets. |
As
a result, the Company has expanded its business model to include the cultivation and retail sale of cannabis in the medicinal cannabis
industry.
Note
2. Basis of Presentation and Summary of Significant Accounting
Policies
Basis
of Accounting
The
accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted
in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management,
the accompanying consolidated financial statements include normal recurring adjustments that are necessary for a fair presentation of
the results for the periods presented.
Principal
of Consolidation
The
consolidated financial statements for the years ended December 31, 2021 and 2020 include the accounts of American Cannabis Company, Inc.
and its wholly owned subsidiary, Hollister & Blacksmith, Inc., doing business as American Cannabis Company, Inc. Intercompany accounts
and transactions have been eliminated.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Going
Concern
Accounting
Standards Codification (“ASC”) Topic 205-40, Presentation of Financial Statements - Going Concern ("ASC
205-40") requires management to assess the Company’s ability to continue as a going concern for one year after the date the
financial statements are issued. Under ASC 205-40, management has the responsibility to evaluate whether conditions and/or events
raise substantial doubt about our ability to meet future financial obligations as they become due within one year after the date that
the financial statements are issued. As required by this standard, management’s evaluation shall initially not take into consideration
the potential mitigating effects of management’s plans that have not been fully implemented as of the date the financial statements
are issued.
Our
assessment included the preparation of a detailed cash forecast that included all projected cash inflows and outflows. During 2021, we
secured additional cash financings through the sales and issuances of our common stock through. However, we continue to focus on growing
our revenues. Accordingly, operating expenditures may exceed the revenue we expect to receive for the foreseeable future. We, also, have
a history of operating losses, negative operating cash flows, and negative working capital, and expect these trends to continue into
the foreseeable future.
As
of the date of this Annual Report on Form 10-K, while we believe we have adequate capital resources to complete our near-term operations,
there is no guarantee that such capital resources will be sufficient until such time we reach profitability. We may access capital markets
to fund strategic acquisitions or ongoing operations on terms we believe are favorable. The timing and amount of capital that may be
raised is dependent on market conditions and the terms and conditions upon which investors would require to provide such capital. We
may utilize debt or sell newly issued equity securities through public or private transactions .
There
can be no assurance that we will be able to obtain additional funding on satisfactory terms or at all. In addition, no assurance can
be given that any such financing, if obtained, will be adequate to meet our capital needs and support our growth. If additional funding
cannot be obtained on a timely basis and on satisfactory terms, our operations would be materially negatively impacted; however, we have
been successful in accessing capital markets in the past, and we are confident in our ability to access capital markets again, if needed.
The
Company has an accumulated deficit, recurring losses, and expects continuing future losses. These factors raise substantial doubt about
the Company’s ability to continue as a going concern. The Company’s primary source of operating funds in 2021 and 2020 has
been from funds generated from proceeds from the sale of common stock and operations. The Company has experienced net losses from operations
since its inception but expects these conditions to improve in 2022 and beyond as it develops its business model. The Company has an
accumulated deficit at December 31, 2021 and requires additional financing to fund future operations.
The
Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding
sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution
of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company
be unable to continue as a going concern.
The
accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets
and the satisfaction of liabilities in the normal course of business.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Use
of Estimates in Financial Reporting
The
preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that
affect the amount of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the consolidated
financial statements during the periods presented. Actual results could differ from these estimates. Estimates and assumptions are reviewed
periodically, and the effects of revisions are reflected in the consolidated financial statements in the period in which they are deemed
to be necessary. Significant estimates made in the accompanying consolidated financial statements include but are not limited to following
those related to revenue recognition, allowance for doubtful accounts and unbilled services, lives and recoverability of equipment and
other long-lived assets, the allocation of the asset purchase price, contingencies, and litigation. The Company is subject to uncertainties,
such as the impact of future events, economic, environmental, and political factors, and changes in the business climate; therefore,
actual results may differ from those estimates. When no estimate in a given range is deemed to be better than any other when estimating
contingent liabilities, the low end of the range is accrued. Accordingly, the accounting estimates used in the preparation of the Company's
consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained
and as the Company's operating environment changes. Changes in estimates are made when circumstances warrant. Such changes and refinements
in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are
disclosed in the notes to the consolidated financial statements.
Segment
Information
Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker, or decision-making group, in deciding how to allocate resources and assess performance. The Company reports
results of operations in 1 segment the Cannabis Industry, with 3 revenue lines: Consulting Services, Soil Product and Equipment and Cannabis
Products.
The
Consulting Services provides services to the Cannabis industry as to the development and expansion of cultivation and retail facilities.
These services include business plans, design advice and cultivation oversight. These services are offered throughout the United States.
The
Soil Product and Equipment handles the sale of our So-Hum Living Soils Product and the resale of Equipment in connection with our consulting
services not only in the Cannabis industry but also to other agricultural industries. These products are offered for sale throughout
the United States.
The
Cannabis Products Division handles both the cultivation of and the retail sale of medicinal cannabis products in the State of Colorado.
Cash
and Cash Equivalents
The
Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash
equivalents are held in operating accounts at a major financial institution. Cash balances may exceed federally insured limits. Management
believes the financial risk associated with these balances is minimal and has not experienced any losses to date. As of December 31,
2021 and 2020, the Company had cash balances in excess of FDIC insured limits of $250,000.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Accounts
Receivable, net
Accounts
receivable are recorded at the net value of face amount less an allowance for doubtful accounts. The Company evaluates its accounts receivable
periodically based on specific identification of any accounts receivable for which the Company deems the net realizable value to be less
than the gross amount of accounts receivable recorded; in these cases, an allowance for doubtful accounts is established for those
balances. In determining its need for an allowance for doubtful accounts, the Company considers historical experience, analysis of past
due amounts, client creditworthiness and any other relevant available information. However, the Company’s actual experience may
vary from its estimates. If the financial condition of its clients were to deteriorate, resulting in their inability or unwillingness
to pay the Company’s fees, it may need to record additional allowances or write-offs in future periods. This risk is mitigated
to the extent that the Company receives retainers from its clients prior to performing significant services.
The
allowance for doubtful accounts, if any, is recorded as a reduction in revenue to the extent the provision relates to fee adjustments
and other discretionary pricing adjustments. To the extent the provision relates to a client's inability to make required payments on
accounts receivables, the provision is recorded in operating expenses. As of December 31, 2021, and 2020, the Company’s allowance
for doubtful accounts was $82,540
and $57,512,
respectively. The Company recorded bad debt expense during the years ended December 31, 2021 and 2020 of $54,435
and $4,910,
respectively.
Deposits
Deposits
is comprised of advance payments made to third parties, for rent, utilities, and inventory for which the Company has not yet taken title.
When the Company takes title to inventory for which deposits are made, the related amount is classified as inventory, then recognized
as a cost of revenues upon sale.
Inventory
Inventory
is comprised of products and equipment owned by the Company to be sold to end-customers. The Company’s inventory as it relates
to its soil products and equipment is valued at cost using the first-in first-out and specific identification methods, unless and until
the market value for the inventory is lower than cost, in which case an allowance is established to reduce the valuation to net realizable
value. As of December 31, 2021 and 2020, market values of all the Company’s inventory were greater than cost, and accordingly,
no such valuation allowance was recognized.
Inventory
also consists of pre-harvested cannabis plants and related end products. Inventory is valued at the lower of cost or net realizable value.
Costs of inventory purchased from third party vendors for retail sales at dispensaries is determined using the first in first out method.
Costs are capitalized to cultivated inventory until substantially ready for sale. Costs include direct and indirect labor, consumables,
materials, packaging supplies, utilities, facilities costs, quality and testing costs, production related depreciation and other overhead
costs. The Company periodically reviews physical inventory for excess, obsolete, and potentially impaired items. The reserve estimate
for excess and obsolete inventory is based on expected future use and on an assessment of market conditions. At December 31, 2021, the
Company’s management determined that a reserve for excess and obsolete inventory was not necessary
Prepaid
Expenses and Other Current Assets
Prepaid
expenses and other current assets are primarily comprised of advance payments made to third parties for independent contractors’
services or other general expenses. Prepaid services and general expenses are amortized over the applicable periods which approximate
the life of the contract or service period.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Significant
Clients and Customers
For
the year ended December 31, 2021, nine customers accounted for 50.1%
of the Company’s total revenues from its consulting and soil and product revenue lines for the period. As of December 31, 2020,
three customers accounted for 84.21%
of the Company’s total revenues.
At
December 31, 2021, two customers accounted for 77.3%
of accounts receivable, net. Accounts Receivable, net consist of customers of our consulting services and soil and products revenue streams.
At December 31, 2020, three customers accounted for 84.21%
of accounts receivables, net.
Property
and Equipment, net
Property
and Equipment is stated at net book value, cost less depreciation. Maintenance and repairs are expensed as incurred. Depreciation of
owned equipment is provided using the straight-line method over the estimated useful lives of the assets, ranging from two to seven years.
Costs associated with in progress construction are capitalized as incurred and depreciation is consummated once the underlying asset
is placed into service. Property and equipment are reviewed for impairment as discussed below under “Accounting for the Impairment
of Long-Lived Assets.” The Company did not capitalize any interest as of December 31, 2021 and 2020.
Goodwill
Goodwill
represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for
goodwill under ASC Topic 350, Intangibles-Goodwill and Other. The Company tests goodwill for impairment annually, or more frequently
whenever events or circumstances indicate impairment may exist. Goodwill is stated at cost less accumulated impairment losses. The Company
completes its goodwill impairment test annually in the fourth quarter. The Company recognized goodwill of $1,985,113
during the year ended December 31, 2021 as part
of the Naturaleaf Acquisition.
The
Company does not have any other indefinite-lived intangible assets.
In
accordance with FASB ASC 350, “Intangibles – Goodwill and Other,” we perform goodwill impairment testing at least annually,
unless indicators of impairment exist in interim periods. The impairment test for goodwill uses a two-step approach. Step one compares
the estimated fair value of a reporting unit with goodwill to its carrying value. If the carrying value exceeds the estimated fair value,
step two must be performed. Step two compares the carrying value of the reporting unit to the fair value of all of the assets and liabilities
of the reporting unit (including any unrecognized intangibles) as if the reporting unit was acquired in a business combination. If the
carrying amount of a reporting unit’s goodwill exceeds the implied fair value of its goodwill, an impairment loss is recognized
in an amount equal to the excess.
Intangible
Assets, net
Definite
life intangible assets at December 31, 2021 include licenses and brand names recognized as part of the Naturaleaf Acquisition. Intangible
assets are record at cost. Licenses and brand names represent the estimated fair value of these items at the date of acquisition, April
30, 2021. Intangible assets are amortized on a straight-line basis over their estimated useful life. Licenses are assigned a life of
15 years and tradenames are assigned a life of 5 years. During the year ended December 31, 2021, the Company recognized an amortization
expense of $62,223.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Accounting
for the Impairment of Long-Lived Assets
The
Company evaluates long lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an
asset may not be recoverable. Upon such an occurrence, recoverability of assets to be held and used is measured by comparing the carrying
amount of an asset to forecasted undiscounted net cash flows expected to be generated by the asset. If the carrying amount of the asset
exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds
the fair value of the asset. For long lived assets held for sale, assets are written down to fair value, less cost to sell. Fair value
is determined based on discounted cash flows, appraised values or management's estimates, depending upon the nature of the assets. The
Company had not recorded any impairment charges related to long lived assets as of December 31, 2021 and 2020.
Fair
Value Measurements
Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date.
Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable,
as follows:
Level
1 – Quoted prices in active markets for identical assets or liabilities.
Level
2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities;
quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for
substantially the full term of the assets or liabilities.
Level
3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair
value of the assets or liabilities.
Our
financial instruments include cash, deposits, accounts receivable, accounts payables, advances from clients, accrued expense, and other
current liabilities. The carrying values of these financial instruments approximate their fair value due to their short maturities.
Revenue
Recognition
We
have adopted the following accounting principles related to revenue recognition: (a) FASB ASU 2016-12 “Revenue from Contracts
with Customers (Topic 606). Due to the nature of our contracts with customers, adopting the new accounting principles did not have
a significant impact on our prior period results of operations, cash flows or financial position.
Our
service and product revenues arise from contracts with customers. Service revenue includes Operations Divisions consulting revenue. Product
revenue includes (a) Operations Division product sales (So-Hum Living Soils), (b) Equipment sales division, (c) Cannabis sales division.
The majority of our revenue is derived from distinct performance obligations, such as time spent delivering a service or the delivery
of a specific product.
We
may also enter into contracts with customers that identify a single, or few, distinct performance obligations, but that also have non-distinct,
underlying performance obligations. These contracts are typically fulfilled within one to six months. Only an insignificant portion of
our revenue would be assessed for allocation between distinct (contractual) performance obligations and non-distinct deliverables between
reporting periods and, accordingly, we do not record a contract asset for completed, non-distinct performance obligations prior to invoicing
the customer.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
We
recognize revenue in accordance with ASC 606 using the following 5 steps to identify revenues:
|
(1) |
Identify the contract
with the Customer. Our customary practice is to obtain written evidence, typically in the form of a contract or purchase
order. |
|
(2) |
Identify the performance
obligations in the contract. We have rights to payment when services are completed in accordance with the underlying contract,
or for the sale of goods when custody is transferred to our customers either upon delivery to our customers’ locations, with
no right of return or further obligations. |
|
(3) |
Determination of the
transaction price. Prices are typically fixed, and no price protections or variables are offered. |
|
(4) |
Allocation of the transaction
price to the performance obligations in the contract. Transaction prices are typically allocated to the performance obligations
outlined in the contract. |
|
(5) |
Recognize Revenue when
(or as) the entity satisfies a performance obligation. We typically require a retainer for all or a portion of the goods
or services to be delivered. We recognize revenue as the performance obligations detailed in the contract are met. |
Advances
from Clients deposits are contract liabilities with customers that represent our obligation to either transfer goods or services in the
future, or refund the amount received. Where possible, we obtain retainers to lessen our risk of non-payment by our customers. Advances
from Clients deposits are recognized as revenue as we meet specified performance obligations as detailed in the contract.
Product
and Equipment Sales
Revenue
from product and equipment sales, including delivery fees, is recognized when an order has been obtained from the customer, the price
is fixed and determinable when the order is placed, the product is delivered, title has transferred, and collectability is reasonably
assured. Generally, our suppliers’ drop-ship orders to our clients with destination terms. The Company realizes revenue upon delivery
to the customer. Given the facts that (1) our customers exercise discretion in determining the timing of when they place their product
order; and, (2) the price negotiated in our product sales contracts is fixed and determinable at the time the customer places the order,
we are not of the opinion that our product sales indicate or involve any significant financing that would materially change the amount
of revenue recognized under the contract, or would otherwise contain a significant financing component for us or the customer under FASB
ASC Topic 606. During the years ended December 31, 2021 and 2020, sales returns were $0.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Consulting
Services
We
also generate revenues from professional services consulting agreements. These arrangements are generally entered into: (1) on an hourly
basis for a fixed fee; or (2) on a contingent fee basis. Generally, we require a complete or partial prepayment or retainer prior to
performing services. For hourly based fixed fee service contracts, we utilize and rely upon the proportional performance method, which
recognizes revenue as services are completed. Under this method, in order to determine the amount of revenue to be recognized, we calculate
the amount of completed work in comparison to the total services to be provided under the arrangement or deliverable. We segregate upon
entry into a contract any advances or retainers received from clients for fixed fee hourly services into a separate “Advances from
Clients” account, and only recognize revenues as we incur and charge billable hours, and then deposit the funds earned into our
operating account. Because our hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon
actual performance, we are of the opinion that such arrangements are not an indicator of a vendor or customer based significant financing,
that would materially change the amount of revenue we recognize under the contract or would otherwise contain a significant financing
component under FASB ASC Topic 606.
Occasionally,
our fixed-fee hourly engagements are recognized under the completed performance method. Some fixed fee arrangements are for completion
of a final deliverable or act which is significant to the arrangement. These engagements do not generally exceed a one-year term. If
the performance is for a final deliverable or act, we recognize revenue under the completed performance method, in which revenue is recognized
once the final act or deliverable is performed or delivered for a fixed fee. Revenue recognition is affected by a number of factors that
change the estimated amount of work required to complete the deliverable, such as changes in scope, timing, awaiting notification of
license award from local government, and the level of client involvement. Losses, if any, on fixed-fee engagements are recognized in
the period in which the loss first becomes probable and reasonably estimable. FASB ASC Topic 606 provides a practical expedient to disregard
the effects of a financing component if the period between payment and performance is one year or less. As our fixed fee hourly engagements
do not exceed one year, no significant customer-based financing is implicated under FASB ASC Topic 606. During the years ended December
31, 2021 and 2020, we incurred no losses from fixed fee engagements that terminate prior to completion. We believe if an engagement terminates
prior to completion, we can recover the costs incurred related to the services provided.
We
primarily enter into arrangements for which fixed and determinable revenues are contingent and agreed upon achieving a pre-determined
deliverable or future outcome. Any contingent revenue for these arrangements is not recognized until the contingency is resolved and
collectability is reasonably assured.
Our
arrangements with clients may include terms to deliver multiple services or deliverables. These contracts specifically identify the services
to be provided with the corresponding deliverable. The value for each deliverable is determined based on the prices charged when each
element is sold separately or by other vendor-specific objective evidence (“VSOE”) or estimates of stand-alone selling prices.
Revenues are recognized in accordance with our accounting policies for the elements as described above (see Product Sales). The elements
qualify for separation when the deliverables have value on a stand-alone basis and the value of the separate elements can be established
by VSOE or an estimated selling price.
While
assigning values and identifying separate elements requires judgment, selling prices of the separate elements are generally readily identifiable
as fixed and determinable as we also sell those elements individually outside of a multiple services engagement. Contracts with multiple
elements typically incorporate a fixed-fee or hourly pricing structure. Arrangements are typically terminable by either party upon sufficient
notice or do not include provisions for refunds relating to services provided.
Reimbursable
expenses, including those relating to travel, other out-of-pocket expenses and any third-party costs, are included as a component of
revenues. Typically, an equivalent amount of reimbursable expenses is included in total direct client service costs. Reimbursable expenses
related to time and materials and fixed-fee engagements are recognized as revenue in the period in which the expense is incurred and
collectability is reasonably assured. Taxes collected from customers and remitted to governmental authorities are recognized as liabilities
and paid to the appropriate government entities.
Cannabis
Sales
Revenues
consist of the retail sale of cannabis and related products. Revenue is recognized at the point of sale for retail customers. Payment
is typically due upon transferring the goods to the customer or within a specified time period permitted under the Company’s credit
policy. Sales discounts were not material during the years ended December 31, 2021 and 2020.
Loyalty
Reward Program
The
Company offers a loyalty reward program to its dispensary customers that provides a discount on purchases based upon the total amount
of a purchase, at the time of purchase. Management has determined that as there is no separate performance obligation to the reward program,
i.e., the accumulation and redemption of points, and as such the Company recognizes the revenue at the time of purchase.
Costs
of Revenues
The
Company’s policy is to recognize costs of revenue in the same manner in conjunction with revenue recognition. Cost of revenue includes
the costs directly attributable to revenue recognition and includes compensation and fees for services, travel and other expenses for
services and costs of products and equipment. Selling, general and administrative expenses are charged to expense as incurred.
Advertising
and Promotion Costs
Advertising
and Promotion costs are included as a component of selling and marketing expense and are expensed as incurred. During the years ended
December 31, 2021 and 2020 these expenses were $116,122
and $9,934,
respectively.
Shipping
and Handling Costs
For
product and equipment sales, shipping and handling costs are included as a component of cost of revenues.
Stock-Based
Compensation
Restricted
shares are awarded to employees and entitle the grantee to receive shares of common stock at the end of the established vesting period.
The fair value of the grant is based on the stock price on the date of grant. We recognize related compensation costs on a straight-line
basis over the requisite vesting period of the award, which to date has been one year from the grant date. During the years ended December
31, 2021 and 2020, stock-based compensation expense for restricted shares for Company employees was $42,207
and $29,970,
respectively. Compensation expense for warrants are based on the fair value of the instruments on the grant date, which is determined
using the Black-Scholes valuation model and are expensed over the expected term of the awards. During the year ended December 31, 2021
and 2020, no warrants were issued as stock compensation.
Research
and Development
As
a component of our equipment and supplies offerings, from time-to-time we design and develop our own proprietary products to meet demand
in markets where current offerings are insufficient. These products include, but are not limited to: The Satchel™, Cultivation
Cube™, So-Hum Living Soils™ and the HDCS™. Costs associated with the development of new products are expensed as incurred
as research and development operating expenses. During the years ended December 31, 2021 and 2020, our research and development costs
were de minimis.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Income
Taxes
The
Company’s corporate status changed from an S Corporation, which it had been since inception, to a C Corporation during the year
ended December 31, 2014. As provided in Section 1361 of the Internal Revenue Code, for income tax purposes, S Corporations are not subject
to corporate income taxes; instead, the owners are taxed on their proportionate share of the S Corporation’s taxable income.
We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated
financial statements or tax returns in accordance with applicable accounting guidance for accounting for income taxes, using currently
enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance when necessary
to reduce deferred tax assets to the amount expected to be realized. For the year ended December 31, 2021, due to cumulative losses since
our corporate status changed, we recorded a valuation allowance against our deferred tax asset that reduced our income tax benefit for
the period to zero. As of December 31, 2021 and 2020, we had no liabilities related to federal or state income taxes and the carrying
value of our deferred tax asset was zero.
Due
to its cannabis operations, the Company is subject to the limitations of Internal Revenue Code (“IRC”) Section 280E
under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences
between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E.
Net
Loss Per Common Share
The
Company reports net loss per common share in accordance with FASB ASC 260, “Earnings per Share”. This statement requires
dual presentation of basic and diluted earnings with a reconciliation of the numerator and denominator of the earnings per share computations.
Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares
of common stock outstanding during the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share
is equal to basic earnings per share because there are no potential dilatable instruments that would have an anti-dilutive effect on
earnings. Diluted net loss per share gives effect to any dilutive potential common stock outstanding during the period. The computation
does not assume conversion, exercise or contingent exercise of securities since that would have an anti-dilutive effect on earnings.
Related
Party Transactions
The
Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure
of related party transactions.
Pursuant
to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities
would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15,
to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit
sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management
of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management
or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate
interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties
or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one
or more of the transacting parties might be prevented from fully pursuing its own separate interests.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Impact
of COVID-19 Pandemic
On March
11, 2020, the World Health Organization declared the current coronavirus (“COVID-19”) outbreak to be a
global pandemic. In response to this declaration and the rapid spread of COVID-19 within the United States, federal, state
and local governments throughout the country have imposed varying degrees of restrictions on social and commercial activity to promote
social distancing in an effort to slow the spread of the illness. These measures had a significant adverse impact upon many sectors of
the economy, including retail commerce.
In
response to state and local measures and for protection of both employees, the Company made required changes to operations, which did
not have a material impact upon operations or the financial condition of the Company.
While
the state and local governments have eased restrictions on restrictions and activities, it is possible that a resurgence in COVID-19 cases
could prompt a return to or new tighter restrictions to be instituted in the future. The Company is not aware of any specific event or
circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities
as of the date of issuance of these consolidated financial statements.
Recent
Accounting Pronouncements
Recent
accounting pronouncements that the Company has adopted or that will be required to adopt in the future are summarized below.
In
December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes”. The pronouncement simplifies
the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, “Income Taxes”.
The pronouncement also improves consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing
guidance. This standard is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The
Company has adopted the standard and there was not an impact on its consolidated financial statements.
In
January 2020, the FASB issued ASU No. 2020-01, "Investments — Equity Securities: Clarifying the Interactions between Topic
321, Topic 323, and Topic 815" ("ASU No. 2020-01"). ASU No. 2020-01 clarifies that an entity should consider observable
transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement
alternative in accordance with ASC 321, "Investments — Equity Securities" immediately before applying or upon
discontinuing the equity method of accounting in ASC 323, "Investments—Equity Method and Joint Ventures." The provisions
of ASU No. 2020-01 are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years with
early adoption permitted, including early adoption in an interim period for public business entities for periods for which financial
statements have not yet been issued. The Company has adopted thee standard and there was not an impact on its consolidated financial
statements.
Note
3. Naturaleaf Asset Acquisition
On
April 30, 2021, the Company closed its acquisition of the assets of Medihemp, LLC, and its wholly owned subsidiary SLAM Enterprises,
LLC, and Medical Cannabis Caregivers, Inc., each an entity organized and operating under the laws of the State of Colorado, and all doing
business as “Naturaleaf” in the medicinal cannabis industry in Colorado.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Naturaleaf
agreed to sell or assign to the Company the following assets:
|
1. |
Three Medical Marijuana
(MMC) Store Licenses; |
|
2. |
One Marijuana Infused Product
Licenses (MIPS); and, |
|
3. |
One Option Premises Cultivation
License (OPC); and, |
|
4. |
Related real property assets,
goodwill, and related business assets. |
The
aggregate consideration paid for the Assets was $2,890,000, which consisted of (i) a cash payment of $1,100,000, (ii) the issuance of
a promissory note to the owner of Naturaleaf in the principal amount of $1,100,000 (the “Seller Note”), and (iii) the issuance
of 3,000,000 shares of the Company’s restricted common stock valued at $0.23 per share or $690,000.
The
asset acquisition was accounted for under the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations.
As the acquirer for accounting purposes, the Company has estimated the fair value of Medihemp LLC and Medical Cannabis Caregivers, Inc.’s
(hereafter “Naturaleaf’s”) assets acquired and conformed the accounting policies of Naturaleaf to its own accounting
policies. The Company expensed certain legal, auditing and licensing costs with the acquisition of $83,095.
As
part of the acquisition, the owners of Naturaleaf retained the outstanding cash balance on the date of the acquisition and had agreed
to the payment of all outstanding accounts payables and related party advances.
The
Company has performed a valuation analysis of the fair market value of Naturaleaf’s assets. The following table summarizes the
allocation of the preliminary purchase price as of the acquisition date:
Schedule of purchase
price as of the acquisition |
|
|
|
|
Cash |
|
$ |
-- |
|
Inventory |
|
|
72,172 |
|
Property, plant and equipment |
|
|
26,715 |
|
Long Term Deposits |
|
|
6,000 |
|
Identifiable intangible assets |
|
|
800,000 |
|
Goodwill |
|
|
1,985,113 |
|
Accounts payable |
|
|
-- |
|
Total consideration |
|
$ |
2,890,000 |
|
Goodwill
from the acquisition primarily relates to the future economic benefits arising from the assets acquired, the assembled workforce acquired
and synergies between the cultivation and retail operations and is consistent with the Company's stated intentions and strategy. Other
assets include inventory and fixed assets.
The
fair value of Naturaleaf’s identifiable intangible assets was $800,000 at April 30, 2021, consisting of $500,000 in licenses and
$300,000 in brand names. During the year ended December 31, 2021, the Company recognized an amortization expense of $62,223.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
The
results of operations of Naturaleaf for the period from April 30, 2021 through December 31, 2021 are included in the Company's consolidated
financial statements as of December 31, 2021.
Pro
Forma Financial Information
The
following pro forma information presents a summary of the Company’s combined operating results for the years ended December
31, 2021 and 2020, as if the acquisition had occurred on January 1, 2020. The following pro forma financial information is not necessarily
indicative of the Company’s operating results as they would have been had the acquisition been effected on the assumed date, nor
is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between
the assumptions used to prepare the pro forma information, basic shares outstanding and dilutive equivalents, cost savings from operating
efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.
Schedule
of pro forma financial information | |
| | | |
| | |
| |
Years
ended |
| |
December
31, |
| |
2021 | |
2020 |
| |
| |
|
Total
Revenues | |
$ | 3,191,742 | | |
$ | 2,898,672 | |
(Loss)
Income from Operations | |
$ | (1,332,564 | ) | |
$ | (139,589 | ) |
| |
| | | |
| | |
Basic
and diluted loss per share | |
$ | — | | |
$ | — | |
Note
4. Accounts Receivable and Advance from Clients
Accounts
receivable was comprised of the following:
Schedule
of Accounts receivable and advance from clients | |
| | | |
| | |
| |
| |
|
| |
December
31, 2021 | |
December
31, 2020 |
Accounts Receivable
– Trade | |
$ | 93,856 | | |
$ | 82,467 | |
Less:
Allowance for Doubtful Accounts | |
| (82,540 | ) | |
| (57,512 | ) |
Accounts
Receivable, net | |
$ | 11,316 | | |
$ | 24,955 | |
The
Company had bad debt expense during the years ended December 31, 2021 and 2020 of $54,435
and $4,910,
respectively.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Our
Advances from Clients had the following activity:
Advances
from Clients |
|
| |
|
| | |
|
|
December
31, 2021 | |
|
December
31, 2020 |
Beginning Balance |
$ |
88,843 | |
|
$ | 112,959 | |
Additional deposits
received |
|
404,143 | |
|
| 481,237 | |
Less:
Deposits recognized as revenue |
|
(381,094 | ) |
|
| (505,363 | ) |
Ending
Balance |
$ |
111,892 | |
|
$ | 88,843 | |
Note
5. Inventory
Inventory
consisted of the following:
Schedule
of inventory | |
| | | |
| | |
| |
| |
|
| |
December
31, 2021 | |
December
31, 2020 |
Raw
Materials - Soil | |
$ | 60,900 | | |
$ | 39,746 | |
Work
In Process - Cultivation | |
| 136,266 | | |
| — | |
Finished
Goods - Soil | |
| 58,594 | | |
| 22,656 | |
Finished
Goods - Cannabis Retail | |
| 22,848 | | |
| 22,656 | |
Total
Inventory | |
$ | 278,608 | | |
$ | 62,402 | |
Note
6. Property and Equipment, net
Property
and equipment, net, was comprised of the following:
Schedule of property
and equipment | |
| |
|
| |
| |
|
| |
December
31, 2021 | |
December
31, 2020 |
Office equipment | |
$ | 39,574 | | |
$ | 34,072 | |
Software | |
| 13,204 | | |
| 13,204 | |
Furniture and Fixtures | |
| 2,328 | | |
| — | |
Machinery and Equipment | |
| 376,745 | | |
| — | |
Leasehold
Improvements | |
| — | | |
| — | |
Property and equipment, gross | |
$ | 431,851 | | |
$ | 47,274 | |
Less:
Accumulated Depreciation | |
| (56,019 | ) | |
| (22,621 | ) |
Property
and equipment, net | |
$ | 375,832 | | |
$ | 24,655 | |
As
part of the Naturaleaf Asset Acquistion, the Company acquired $26,715 in fixed assets consisting of machinery and equipment. During the
year ended December 31, 2021, the Company purchased office equipment in the amount of $5,500 and has made purchases of machinery and
equipment of $352,301 in order to upgrade operations at the new cultivation facilities.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Note
7. Intangible Assets, Net
A
significant amount of the Company’s current identified intangible assets were assumed upon consummation of the Naturaleaf acquisition
on April 30, 2021. The Company has incurred capitalizable costs in connection with patent applications that it started work on. Identified
intangible assets consisted of the following at the dates indicated below:
Schedule
of intangible assets | |
| | | |
| | | |
| | | |
| | |
| |
December
31, 2021 |
| |
Gross
carrying amount | |
Accumulated
amortization | |
Carrying
value | |
Estimated
useful life |
Licenses | |
$ | 500,000 | | |
($ | 22,223 | ) | |
$ | 477,777 | | |
| 15
years | |
Brand | |
$ | 300,000 | | |
($ | 40,000 | ) | |
$ | 260,000 | | |
| 5
years | |
Patent
Applications | |
$ | 8,160 | | |
| — | | |
$ | 8,160 | | |
| — | |
Total
intangible assets, net | |
$ | 808,160 | | |
($ | 62,223 | ) | |
$ | 745,937 | | |
| | |
The
weighted-average amortization period for intangible assets we acquired during the year ended December 31, 2021 was approximately 11.47
years. There were no intangible assets acquired during the year ended December 31, 2020.
Amortization
expense for intangible assets was $62,223 and
$0 for
the years ended December 31, 2021 and 2020, respectively. Total estimated amortization expense for our intangible assets for the years
2021 through 2026 is as follows:
| Schedule
of estimated amortization expense | | |
| | |
Year
Ended December
31, | |
|
| 2022 | | |
$ | 93,333 | |
| 2023 | | |
$ | 93,333 | |
| 2024 | | |
$ | 93,333 | |
| 2025 | | |
$ | 93,333 | |
| 2026 | | |
$ | 53,333 | |
| Thereafter | | |
$ | 311,112 | |
Note
8. Accrued and Other Current Liabilities
Accrued
and other current liabilities consisted of the following:
Schedule
of accrued and other current liabilities | |
| | | |
| | |
| |
| |
|
| |
December
31, 2021 | |
December
31, 2020 |
Accrued
Interest | |
$ | 74,137 | | |
$ | 449 | |
Accrued
Payroll | |
| 18,428 | | |
| — | |
Sales
Tax Payable | |
| 592 | | |
| — | |
Other
Accrued Expenses & Payables | |
| 68,561 | | |
| 48,795 | |
Accrued
and other current liabilities. | |
$ | 161,718 | | |
$ | 49,244 | |
Note
9. Stock Payable
The
following summarizes the changes in common stock payable:
Schedule of stock
payable | |
|
| |
Amount |
December 31, 2020 | |
$ | — | |
Additional
Expenses Incurred | |
| 42,207 | |
Payments Upon
Issuance of Shares | |
| — | |
December
31, 2021 | |
$ | 42,207 | |
Note
10. Operating Lease Right-of-Use Asset/Operating Lease Liability
The
Company leases property under operating leases. Property leases include retail and cultivation space with fixed rent payments and lease
terms ranging from one to two years. The Company is obligated to pay the lessor for maintenance, real estate taxes, insurance and other
operating expenses on certain property leases. These expenses are variable and are not included in the measurement of the lease asset
or lease liability. These expenses are recognized as variable rent expense when incurred.
The
Company’s lease portfolio consists of the following.
Schedule of lease
portfolio | |
| |
| |
| |
|
Lease
Name | |
Asset
Type | |
Start
Date | |
Expiration
Date | |
Monthly
Rent |
Durango
Lease | |
Real
Property | |
5/1/2021 | |
5/31/2022 | |
$ | 10,200 | |
Lehman
Lease | |
Real
Property | |
5/1/2021 | |
12/31/2022 | |
$ | 2,732 | |
Palmer
Lease | |
Real
Property | |
5/1/2021 | |
6/30/2022 | |
$ | 1,069 | |
Greenspace
Membership | |
Real
Property | |
4/15/2021 | |
12/31/2021 | |
$ | 1,000 | |
Tejon
Lease | |
Real
Property | |
5/1/2021 | |
4/30/2022 | |
$ | 3,700 | |
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
On
June 1, 2020, the Company entered into a new lease membership agreement for a one-year term for an amount of $2,895 per month, the lease
expired on May 31, 2021. At that time the Company entered into an 8 ½ month lease for less space for an amount of $1,000 per month.
We determined under ASC 842, due to the short-term nature of the lease that the lease membership agreement met the criteria of ASC 842-20-25-2
and as such it was not necessary to capitalize the lease and rent will be recognized on a monthly straight-line basis.
On
May 1, 2020, as part of the Naturaleaf Acquisition, the Company entered into leases for grow facilities and dispensaries. These leases
were determined to be operating leases under ASC 842 and such leases was capitalized. It was determined that the Tejon lease, due to
the short-term nature of the lease met the criteria of ASC 842-20-25-2 and as such it was not necessary to capitalize the lease and rent
would be recognized on a straight-line basis.
The
Company records the lease asset and lease liability at the present value of lease payments over the lease term. The leases typically
do not provide an implicit rate; therefore, the Company uses its estimated incremental borrowing rate at the time of lease commencement
to discount the present value of lease payments. The Company’s discount rate for operating leases at December 31, 2021 was 12.5%.
Leases often include rental escalation clauses, renewal options and/or termination options that are factored into the determination of
lease payments when appropriate. Lease expense is recognized on a straight-line basis over the lease term to the extent that collection
is considered probable. As a result, the Company been recognizing rents as they become payable.
As
of December 31, 2021, the aggregate remaining annual lease payments of operating leases liabilities are as follows:
Schedule
of operating leases liabilities | |
|
| |
Operating
Leases |
2022 | |
$ | 99,684 | |
Total | |
| 99,684 | |
Less:
amount representing interest | |
| (3,962 | ) |
Present value of future minimum
lease payments | |
| 95,722 | |
Less:
current obligations under leases | |
| 95,722 | |
Long-term
lease obligations | |
$ | — | |
As
of December 31, 2021, the aggregate remaining minimal annual lease payments under these operating leases were as follows:
| Schedule
of remaining minimal annual lease payments | | |
| | |
| 2022 | | |
$ | 99,684 | |
| Total | | |
$ | 99,684 | |
Note
11. Loans Payable
PPP
Loans
On
March 27, 2020, the CARES Act was enacted to provide financial aid to family and businesses impacted by the COVID-19 pandemic. The Company
participated in the CARES Act, and on August 6, 2020, the Company entered into a note payable with a bank under the Small Business Administration
(“SBA”) Paycheck Protection Program (“PPP loan”) in the amount of $109,914. This loan payable matures on August
6, 2022 with a fixed interest rate of 1% per annum with interest deferred for six months. The PPP loan has an initial term of two years,
is unsecured and guaranteed by the SBA. Under the terms of the PPP loan, the Company may apply for forgiveness of the amount due on the
PPP loan. The Company used the proceeds from the PPP loan for qualifying expenses as defined in the PPP. The Company intends to apply
for forgiveness of the PPP loan in accordance with the terms of the CARES Act. However, the Company cannot assure at this time that the
PPP loan will be forgiven partially or in full. If the loan is not forgiven based on the PPP guidelines to be issued by the SBA, as defined,
then, the monthly payment amount will be $6,186 beginning on March 6, 2021 through August 6, 2022. On March 3, 2021, the SBA forgave
the principal of $109,914 and accrued interest of $875 at that time..
On
April 23, 2021, the Company entered into a second note payable with a bank under the SBA PPP Loan in the amount of $130,186. The PPP
Loan is subject to the same terms of forgiveness as above. On September 27, 2021, the SBA forgave the principal of $130,186 and any accrued
interest.
Naturaleaf
Seller Note
As
part of the Naturaleaf Acquisition, the Company issued a promissory note to the owner of Naturaleaf in the principal amount of $1,100,000
(the “Seller Note”). The note has a term of 1 year with a due date of April 30, 2022 and does not require any payments prior
to the due date. The note has an annual interest rate of 10%. At December 31, 2021, interest of $74,137 had been accrued.
Note
12. Related Party Transactions
The
Company has a related party entity, Tabular Investments, LLC (“Tabular”) which was set to assign the Company’s interest
in various equity partnership. The sole member of Tabular is Tad Mailander, the Company’s outside legal counsel and Director. The
Company has valued all of its equity partnership investments at $0. Neither our direct equity ownership in, nor our assignments of equity
to Tabular Investments, LLC are, or are reasonably likely to allow for, substantive terms, transactions, and arrangements, whether contractual
or not contractual, that will have a current or future effect on our financial condition, revenues or expenses, results of operations,
liquidity, capital expenditures or capital resources. We have no direct or indirect majority influence or control over any entity in
which we have a direct equity interest or equity interests assigned to Tabular. We do not have any direct or indirect interest in, and
do not control Tabular. We have not absorbed losses from either our direct equity interests or assignments to Tabular and do not expect
to, and we have provided no subordinated financial support to any project
Note
13. Stock Based Compensation
During
the year ended December 31, 2021, the Company issued stock-based compensation for employees and service providers pursuant to its 2015
Equity Incentive Plan.
Restricted
Shares
From
time to time, the Company grants certain employees restricted shares of its common stock to provide further compensation in-lieu of wages
and to align the employee’s interests with the interests of its stockholders. Because vesting is based on continued employment,
these equity-based incentives are also intended to attract, retain and motivate personnel upon whose judgment, initiative and effort
the Company’s success is largely dependent.
During
the year ended December 31, 2021, the Company granted 275,000 restricted shares and recognized $42,207 in associated employee stock-based
compensation expense. The fair value of restricted stock unit is determined based on the quoted closing price of the Company’s
common stock on the date grant. As of December 31, 2021, none of the shares were issued, and the entire amount is recorded as stock payable.
During
the year ended December 31, 2020, the Company granted 492,567 restricted shares and recognized $29,970 in associated employee stock-based
compensation expense. The fair value of the restricted stock is determined based on the quoted closing price of the Company’s common
stock on the date of grant. During the years ended December 31, 2020, the Company issued 478,261 shares of restricted shares granted
during the fiscal year ended December 31, 2019.
During
the year ended December 31, 2020, the Company issued 78,505 restricted common shares to two employees in payment of commissions earned
totaling $7,066.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Net
Loss Per Share
Basic
net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the reporting
period. Diluted net loss per share is computed similarly to basic loss per share, except that it includes the potential dilution that
could occur if dilutive securities are exercised.
Outstanding
stock options and common stock warrants are considered anti-dilutive because we are in a net loss position. Accordingly, the number of
weighted average shares outstanding for basic and fully diluted net loss per share are the same.
The
following summarizes equity instruments that may, in the future, have a dilutive effect on earnings per share:
Schedule of stock
based compensation | |
| |
|
| |
December
31, 2021 | |
December
31, 2020 |
Warrants | |
| — | | |
| 397,500 | |
Stock
Payable | |
| 275,000 | | |
| — | |
Total | |
| 275,000 | | |
| 397,500 | |
Warrants
During
the year ended December 31, 2021, 125,000 shares of common stock were issued to in connection with the cashless exercise of 125,000 warrants,
100,000 of these shares were issued to an officer and director of the Company.
During
the year ended December 31, 2021, the Company did not issue or approve any warrants. Warrants exercisable for 272,500 shares expired.
Note
14. Shareholders’ Equity
Preferred
Stock
American
Cannabis Company, Inc. is authorized to issue 5,000,000 shares of preferred stock at $0.01 par value. No shares of preferred stock were
issued and outstanding at December 31, 2021 and 2020, respectively.
Common
Stock
During
the year ended December 31, 2021, the Company issued 8,050,000 registered shares of common stock in exchange for net proceeds of $1,241,043
pursuant to the Common Stock Purchase Agreement entered into on October 11, 2019 with White Lion Capital LLC.
During
the year ended December 31, 2021, the Company issued 3,000,000 shares of its restricted common stock to the sellers of Naturaleaf, as
part of the acquisition of assets of Naturaleaf. The shares had a value of $690,000 based on a closing market price on April 30, 2021
of $0.23 per share.
During
the year ended December 31, 2021, warrants with a cashless exercise provision were exercised for 125,000 restricted shares . Of which,
a warrant for 100,000 shares was exercised by an officer/director of the Company.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
During
the years ended December 31, 2020, the Company issued 478,261 shares of restricted shares granted during the fiscal year ended December
31, 2019.
Note
15. Commitments and Contingencies
Legal
In
the ordinary course of its business, the Company becomes involved in various legal proceedings involving a variety of matters. The Company
does not believe there are any pending legal proceedings that will have a material adverse effect on the Company’s business, consolidated
financial position, results of operations, or cash flows. However, the outcome of such legal matters is inherently unpredictable and
subject to significant uncertainties. The Companies expenses legal fees in the period in which they are incurred.
Employment
Litigation
On
November 15, 2019, a civil action was filed against the Company and Mr. Terry Buffalo, our former chief executive officer and director,
and Mr. Ellis Smith our chief development officer and director, in Denver County District Court, Case Number 2019CV034380. The complaint
sought a declaratory judgement and damages related to Plaintiff’s allegation that she was misclassified as an independent contractor
while working for the Company. Plaintiff alleged she was owed unpaid overtime, liquidated damages, wages, statutory penalties and other
compensatory damages for her misclassification and alleged wrongful termination. Plaintiff’s suit against Mr. Buffalo and
Mr. Smith alleges that each were the alter ego of the Company and are therefore jointly and severally liable. The Company filed
a counterclaim against Plaintiff alleging misappropriation of trade secrets, breach of contract, and other claims relating to her theft
of confidential and proprietary information. A Settlement Agreement was entered into by all parties in January 2022. At December 31,
2021, there was a reasonable basis from which a determination could be made concerning the amount of a possible liability to the Company
as its related to this lawsuit.
The
Settlement Agreement provides for a cash settlement of $350,000 to be paid over a 2 year period and as a result at December 31, 2021,
the Company has recognized a total of liability of $350,000,
of which $175,000
is classified as current.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Note
16. Income Taxes
The
following table displays a reconciliation from the U.S. statutory rate to the effective tax rate and the provision for (benefit from)
income taxes for the years ended December 31, 2021 and 2020, respectively:
Schedule
of income tax rate | |
| | | |
| | |
| |
For
the Years Ended |
| |
December
31, | |
December
31, |
| |
2021 | |
2020 |
| |
| |
|
Income
Tax Benefit | |
$ | (623,358 | ) | |
$ | (38,021 | ) |
Non-deductible
expenses including non-deductible pre-merger losses | |
| 163,495 | | |
| — | |
Change
in valuation allowance | |
| 459,863 | | |
| 38,021 | |
Total
Income Tax Benefit | |
$ | — | | |
$ | — | |
Deferred
tax assets (liabilities) consisted of the following:
Schedule
of deferred tax assets | |
| | | |
| | |
| |
December
31, | |
December
31, |
| |
2021 | |
2020 |
| |
| |
|
Total
Deferred Tax Liabilities | |
| | | |
| | |
Lease
Liability Expense | |
$ | (24,457) | | |
$ | — | |
Total
Deferred Tax Assets | |
| | | |
| | |
Net
operating loss carryforwards | |
| 1,230,904 | | |
| 770,558 | |
Beneficial
Conversion feature | |
| — | | |
| 3,524 | |
Right
of Use Asset | |
| 24,457 | | |
| — | |
Allowance
for Doubtful Accounts | |
| 17,735 | | |
| 14,694 | |
Net
Deferred Tax Assets | |
| 1,248,639 | | |
| 788,776 | |
Valuation
Allowance | |
| (1,248,639) | | |
| (788,776 | ) |
Total
Deferred Tax Assets | |
$ | — | | |
$ | — | |
The
Company determined that it is not more likely than not that its deferred tax asset would be realizable. accordingly, the Company recorded
a valuation allowance for the full amount of its deferred tax asset, resulting in a zero carrying value of the Company’s deferred
tax asset and no benefit from or provision for income taxes for the year ended December 31, 2021 and 2010. Federal and state operating
loss carry forwards are $4,812,598 and $3,669,322 as of December 31, 2021 and 2020, respectively and begin to expire in 2034. The years
2010 to 2018 remain subject to examination by the Company’s major tax jurisdictions. Utilization of the net operating loss carry
forwards and credits may be subject to a substantial annual limitation due to ownership change limitations provided by Section 382 of
the Internal Revenue Code of 1986, as amended, and similar state provisions.
AMERICAN
CANNABIS COMPANY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2021 AND 2020
Note
17. Subsequent Events
In
accordance with ASC 855-10, the Company has analyzed its operations after consolidated financial statements were available to be issued
and has determined that there were no other significant subsequent events or transactions that would require recognition or disclosure
in the consolidated financial statements for the year ended December 31, 2021, other than as follows.
During
the three months ended March 31, 2022, the Company issued 2,500,000 registered shares of common stock in exchange for net proceeds of
approximately $117,000 pursuant to the Common Stock Purchase Agreement entered into on October 11, 2019 with White Lion Capital
LLC.
During
the three months ended March 31, 2022, the Company issued to its officers and directors 325,000 shares of its restricted common stock
as payment of stock based compensation earned in 2022 totaling $42,207.
SUPPLEMENTARY
DATA
The
Company is a smaller reporting Company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information required
under this item.